Cancer is a disease that requires a huge cost for treatment. The amount of costs that should not be burdensome if managed well with the social insurance mechanisms, such as those mandated by the National Social Security System.
This was revealed in a discussion forum about the cost of cancer treatment, held the Faculty of Public Health University of Indonesia (FKM UI), Wednesday (11 / 5) in Jakarta. According to the World Health Statistics 2008, cancer deaths in Indonesia 132 per 100,000 population.
Professor of FKM UI Hasbullah Thabrany said, Indonesia is in a phase where the incidence of cancer continues to increase. On the other hand, only about 50 percent of people have health insurance in its various forms. For treatment of lung cancer, for example, it takes $ 25 million per month with the drug erlotinib. To think about how to arrange financing that is not burdensome.
This was revealed in a discussion forum about the cost of cancer treatment, held the Faculty of Public Health University of Indonesia (FKM UI), Wednesday (11 / 5) in Jakarta. According to the World Health Statistics 2008, cancer deaths in Indonesia 132 per 100,000 population.
Professor of FKM UI Hasbullah Thabrany said, Indonesia is in a phase where the incidence of cancer continues to increase. On the other hand, only about 50 percent of people have health insurance in its various forms. For treatment of lung cancer, for example, it takes $ 25 million per month with the drug erlotinib. To think about how to arrange financing that is not burdensome.
Guarantee financing cancer treatment has been carried out by PT Askes with participants of civil servants. General Manager of PT Askes (Persero) Regional IV Jakarta Fajriadinur say, the entire cost of cancer treatment is guaranteed by PT Askes. As an illustration, in 2010 PT Askes spend Rp 88 billion for cancer drugs and $ 40 billion for hospitalization. "Cancer affects many participants Askes include breast cancer, cervical, ovarian, nasopharyngeal, lung, prostate, rectum, and stomach," he said.
PT Askes do the management of cancer treatment with farmakoekonomi approach. They create drug formularies with experts taking into account the drug benefit, security, and economic aspects. Also draw attention to the treatment of cancer quality of life of patients with treatment obtained. "If you want to stick together, the cost can be reduced without reducing quality. PT Askes open up opportunity to all drug manufacturers to provide competitive pricing, "he said.
Budi Hidayat said of the FKM UI, management does not stop the funding of cancer treatment, but need to be arranged ranging from prevention, early detection, and palliative care to relieve the suffering of cancer patients.
If cancer is found at an early stage, a person's ability to survive longer and can live productive.
